Clobazam for patients with Lennox-Gastaut syndrome and epilepsy

Expert Review of Neurotherapeutics

Volumn 12, Issue 4, 2012, Pages 385-393

  Seif Eddeine, Hussam ^a   Ng, Yu Tze ^b  

^a BARROW NEUROLOGICAL INSTITUTE   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

1,5 benzodiazepine; clobazam; drop attacks; drop seizures; Lennox Gastaut syndrome; refractory epilepsy; refractory seizures

Indexed keywords

ANTIFUNGAL AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CIMETIDINE; CLARITHROMYCIN; CLOBAZAM; DEXAMETHASONE; DILTIAZEM; ERYTHROMYCIN; FELBAMATE; FLUOXETINE; FLUVOXAMINE; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; HYPERICUM PERFORATUM EXTRACT; LAMOTRIGINE; NEFAZODONE; OMEPRAZOLE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PLACEBO; RIFABUTIN; RIFAMPICIN; SERTRALINE; TICLOPIDINE; TOPIRAMATE; VALPROIC ACID;

AGGRESSION; ANTICONVULSANT ACTIVITY; ARTICLE; ASPIRATION; ATONIC SEIZURE; BENIGN CHILDHOOD EPILEPSY; CONSTIPATION; DEPRESSION; DIPLOPIA; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERANCE; DRUG WITHDRAWAL; EOSINOPHILIA; EPILEPSY; FEVER; GRAPEFRUIT JUICE; HUMAN; HYPERSALIVATION; HYPOMANIA; INSOMNIA; LENNOX GASTAUT SYNDROME; LETHARGY; LOW DRUG DOSE; NONHUMAN; PNEUMONIA; RESPIRATORY DISTRESS; ROLANDIC EPILEPSY; SEDATION; SEIZURE; SIDE EFFECT; SLEEP APNEA SYNDROME; SOMNOLENCE; THROMBOCYTOPENIA; TRANQUILIZING ACTIVITY; UNSPECIFIED SIDE EFFECT; VERTIGO; WEAKNESS;

ANTICONVULSANTS; BENZODIAZEPINES; CLINICAL TRIALS AS TOPIC; DRUG INTERACTIONS; ELECTROENCEPHALOGRAPHY; EPILEPSY; HUMANS; INTELLECTUAL DISABILITY; SPASMS, INFANTILE; TREATMENT OUTCOME;

EID: 84860283336     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/ern.12.14     Document Type: Article

References (99)

1. Gastaut H. Exceptional and unrecognized antiepileptic properties of a commercial anxiolytic: Clobazam [in French]. Concours Med. 100, 3697-3701 (1978).
2. Gastaut H, Low MD. Antiepileptic properties of clobazam, a 1-5 benzodiazepine, in man. Epilepsia 20(4), 437-446 (1979). (Pubitemid 9208031)
3. Fielding S, Lal H. A review of the animal pharmacology of clobazam: An update. Drug Dev. Res. 2(S1), 17-21 (1982). (Pubitemid 12020506)
4. Canadian Clobazam Cooperative Group. Clobazam in treatment of refractory epilepsy: The Canadian experience. A retrospective study. Epilepsia 32(3), 407-416 (1991).
5. Chapman AG, Horton RW, Meldrum BS. Anticonvulsant action of a 1,5-benzodiazepine, clobazam, in reflex epilepsy. Epilepsia 19(3), 293-299 (1978). (Pubitemid 8367462)
6. Ng YT, Collins SD. Clobazam. Neurotherapeutics 4(1), 138-144 (2007). (Pubitemid 46107321)
7. Sugai K. Clobazam as a new antiepileptic drug and clorazepate dipotassium as an alternative antiepileptic drug in Japan. Epilepsia 45(Suppl. 8), 20-25 (2004). (Pubitemid 39648264)
8. Sankar R. GABA(A) receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam. CNS Drugs 26(3), 229-244 (2012).
9. Doi T, Ueda Y, Tokumaru J, Willmore LJ. Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. Brain Res. Mol. Brain Res. 142(2), 91-96 (2005). (Pubitemid 41681276)
10. Olsen RW, Sieghart W. International Union of Pharmacology. LXX. Subtypes of gamma-aminobutyric acid(A) receptors: Classification on the basis of subunit composition, pharmacology, and function. Update. Pharmacol. Rev. 60(3), 243-260 (2008).
11. Nakajima H. A pharmacological profile of clobazam (Mystan), a new antiepileptic drug [In Japanese]. Nippon Yakurigaku Zasshi 118(2), 117-122 (2001). (Pubitemid 32734656)
12. Leonard B. A review of the pharmacological properties of the benzodiazepine anxiolytics. In:Benzodiazepines . Trimble MR, Hindmarch I (Eds). Wrightson Biomedical Publishing Inc., Petersfield, UK, 1-16 (2000).
13. Kinoshita M, Ikeda A, Begum T, Terada K, Shibasaki H. Efficacy of low-dose, add-on therapy of clobazam (CLB) is produced by its major metabolite, N-desmethyl-CLB. J. Neurol. Sci. 263(1-2), 44-48 (2007). (Pubitemid 350029828)
14. Sennoune S, Mesdjian E, Bonneton J, Genton P, Dravet C, Roger J. Interactions between clobazam and standard antiepileptic drugs in patients with epilepsy. Ther. Drug Monit. 14(4), 269-274 (1992).
15. Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther. Drug Monit. 21(6), 604-608 (1999).
16. Fielding S, Hoffmann I. Pharmacology of anti-anxiety drugs with special reference to clobazam. Br. J. Clin. Parmacol. 7(S1), 7S-15S (1979). (Pubitemid 9153373)
17. Greenblatt DJ, Divoll M, Puri SK, Ho I, Zinny MA, Shader RI. Clobazam kinetics in the elderly. Br. J. Clin. Pharmacol. 12(5), 631-636 (1981). (Pubitemid 11027975)
18. Haigh, JR, Pullar, T, Gent, JP, Dailley C, Feely M. N-desmethylclobazam: A possible alternative to clobazam in the treatment of refractory epilepsy. Br. J. Clin. Pharmacol. 23(2), 213-218 (1987). (Pubitemid 17113499)
19. Nakamura F, Suzuki S, Nishimura S, Yagi K, Seino M. Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture. Epilepsia 37(8), 728-735 (1996). (Pubitemid 26276940)
20. Fisher JL. Interactions between modulators of the GABAA receptor: Stiripentol and benzodiazepines. Eur. J. Pharmacol. 654(2), 160-165 (2011). Demonstrated the action of clobazam and norclobazam on the recombinant GABAA receptor, and led to a better understanding of their mechanism of action.
21. Brogden RN, Heel RC, Speight TM, Avery GS. Clobazam: A review of its pharmacological properties and therapeutic use in anxiety. Drugs 20(3), 161-178 (1980). (Pubitemid 11233588)
22. Rupp W, Badian M, Christ O et al. Pharmacokinetics of single and multiple doses of clobazam in humans. Br. J. Clin. Pharmacol. 7(S1), 51S-57S (1979). (Pubitemid 9154215)
23. Anderson GD, Miller JW. Benzodiazepines: Chemistry, biotransformation, and pharmacokinetics. In:Antiepileptic Drugs. Levy RH, Mattson RH, Meldrum BS, Peracca E (Eds). Lippincott Williams & Wilkins, PA, USA, 187-205 (2002).
24. Divoll M, Greenblatt DJ, Ciraulo DA, Puri SK, Ho I, Shader RI. Clobazam kinetics: Intrasubject variability and effect of food on adsorption. J. Clin. Pharmacol. 22(1), 69-73 (1982). (Pubitemid 12185379)
25. Cenraud B, Guyot M, Levy RH et al. No effect of food intake on clobazam absorption. Br. J. Clin. Pharmacol. 16(6), 728-730 (1983). (Pubitemid 14208217)
26. Contin M, Sangiorgi S, Riva R, Parmeggiani A, Albani F, Baruzzi A. Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. Ther. Drug Monit. 24(6), 737-741 (2002). (Pubitemid 35379527)
27. Robertson MM. The place of clobazam in the treatment of epilepsy: An update. Hum. Psychopharmacol. 10(Suppl. 1), S43-S63 (1995).
28. Tolbert DS, Reid M, Walzer A et al. Oral pharmacokinetics of clobazam in normal subjects. AAPS Annual Meeting and Exposition, Los Angeles, CA, USA, 8-12 November 2009. One of the most recent studies on clobazam pharmacokinetics.
29. Tedeschi G, Riva R, Baruzzi A. Clobazam plasma concentrations: Pharmacokinetic study in healthy volunteers and data in epileptic patients. Br. J. Clin. Pharmacol. 11(6), 619-622 (1981). (Pubitemid 11112445)
30. Dehnerdt M, Boenigk H. Clobazam (Frisium) for the treatment of complications of epilepsy [in German]. In: Epilepsy: Psychological Aspects, Post-traumatic Epilepsy, Drug Treatment, Diagnostic Methods. Meeting of the German Section of the International League Against Epilepsy in Berlin. Remschmidt H, Rentz R, Jungmann JE (Eds). Georg Thieme, Stuttgart, Germany, 172-175 (1980).
31. Bun H, Monjanel-Mouterde S, Noel F, Durand A, Cano JP. Effects of age and antiepileptic drugs on plasma levels and kinetics of clobazam and N-desmethylclobazam. Pharmacol. Toxicol. 67(2), 136-140 (1990). (Pubitemid 20354494)
32. Cocks A, Critchley EMR, Hayward HW. The effects of clobazam on the blood levels of sodium valproate. In: Clobazam: Human Psychopharmacology and Clinical Applications. Hindmarch I, Stonier PD, Trimble MR (Eds). Royal Society of Medicine, London, UK, 155-157 (1985).
33. Yagi K, Seino M, Takeda A, et al. Open clinical trials of NH-15 (clobazam) in refractory epilepsies: Early Phase II study and long-term study. Jpn. J. Neuropsychopharmacol. 17, 161-173 (1995).
34. Theis JG, Koren G, Daneman R et al. Interactions of clobazam with conventional antiepileptics in children. J. Child Neurol. 12(3), 208-213 (1997). (Pubitemid 27184797)
35. Luszczki JJ, Trojnar MK, Ratnaraj N, Patsalos PN, Czuczwar SJ. Interactions of stiripentol with clobazam and valproate in the mouse maximal electroshock-induced seizure model. Epilepsy Res. 90(3), 188-198 (2010).
36. Shimizu H, Kawasaki J, Yuasa S, Tarao Y, Kumagai S, Kanemoto K. Use of clobazam for the treatment of refractory complex partial seizures. Seizure 12(5), 282-286 (2003). (Pubitemid 36806073)
37. Patsalos PN, Fröscher W, Pisani F, van Rijn CM. The importance of drug interactions in epilepsy therapy. Epilepsia 43(4), 365-385 (2002). (Pubitemid 34297175)
38. Bardy AH, Seppälä T, Salokorpi T, Granström ML, Santavuori P. Monitoring of concentrations of clobazam and norclobazam in serum and saliva of children with epilepsy. Brain Dev. 13(3), 174-179 (1991).
39. Guberman A. Monotherapy or polytherapy for epilepsy? Can. J. Neurol. Sci. 25(4), S3-S8 (1998). (Pubitemid 28516914)
40. Genton P, Nguyen VH, Mesdjian E. Carbamazepine intoxication with negative myoclonus after the addition of clobazam. Epilepsia 39(10), 1115-1118 (1998). (Pubitemid 28458044)
41. Zifkin B, Sherwin A, Andermann F. Phenytoin toxicity due to interaction with clobazam. Neurology 41(2 Pt 1), 313-314 (1991).
42. Bauer J, Pfeiffer C, Burr W. Which factors have an impact on levetiracetam serum concentrations? An analysis in 163 patients with epilepsy [In German]. Nervenarzt 81(4), 391-395 (2010).
43. Grigoleit HG, Hajdú P, Hundt HK et al. Pharmacokinetic aspects of the interaction between clobazam and cimetidine. Eur. J. Clin. Pharmacol. 25(1), 139-142 (1983). (Pubitemid 13072420)
44. Gerbal-Chaloin S, Pascussi J-M, Pichard-Garcia L et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab. Dispos. 29(3), 242-251 (2001). (Pubitemid 32179522)
45. Rae JM, Johnson MD, Lippman ME, Flockhart DA. Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays. J. Pharmacol. Exp. Ther. 299(3), 849-857 (2001). (Pubitemid 33104951)
46. Wang LS, Zhou G, Zhu B et al. St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin. Pharm. Ther. 75(3), 191-197 (2004). (Pubitemid 38314868)
47. Goshman L, Fish J, Roller K. Clinically significant P450 drug interactions. J. Pharm. Soc. Wis. 1999, 23-38 (1999).
48. Veronese ME, Mackenzie PI, Doecke CJ, McManus ME, Miners JO, Birkett DJ. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem. Biophys. Res. Commun. 175(3), 1112-1118 (1991).
49. Conry JA, Ng YT, Paolicchi JM et al. Clobazam in the treatment of Lennox-Gastaut syndrome. Epilepsia 50(5), 1158-1166 (2009). Phase II (prospective, double-blind, dosage-ranging) study on the effect of clobazam on Lennox-Gastaut syndrome.
50. Kilpatrick C, Bury R, Fullinfaw R, Moulds R. Clobazam in the treatment of epilepsy. Clin. Exp. Neurol. 23, 139-144 (1987).
51. Koeppen D, Baruzzi A, Capozza M et al. Clobazam in therapy-resistant patients with partial epilepsy: A double-blind placebo-controlled crossover study. Epilepsia 28(5), 495-506 (1987). (Pubitemid 17146597)
52. Schmidt D, Rohde M, Wolf P, Roeder-Wanner U. Clobazam for refractory focal epilepsy: A controlled trial. Arch. Neurol. 43(8), 824-826 (1986). (Pubitemid 16034233)
53. Keene DL, Whiting S, Humphreys P. Clobazam as an add-on drug in the treatment of refractory epilepsy of childhood. Can. J. Neurol. Sci. 17(3), 317-319 (1990). (Pubitemid 20254758)
54. Rose W, Kirubakaran C, Scott JX. Intermittent clobazam therapy in febrile seizures. Indian J. Pediatr. 72(1), 31-33 (2005). (Pubitemid 40278861)
55. Allen JW, Oxley J, Robertson MM, Trimble MR, Richens A, Jawad SS. Clobazam as adjunctive treatment in refractory epilepsy. Br. Med. J. 186(6373), 1246-1247 (1983). (Pubitemid 13112080)
56. Ng YT, Conry JA, Drummond R et al. Randomized, Phase III study results of clobazam for seizures associated with Lennox-Gastaut syndrome. Neurology 77(15), 1473-1481 (2011).This Phase III multicenter, double-blind, placebo-controlled study is the largest study conducted in Lennox-Gastaut syndrome.
57. Buchanan N. Clobazam in the treatment of epilepsy: Prospective follow-up to 8 years. J. R. Soc. Med. 86(7), 378-380 (1993). (Pubitemid 23196171)
58. Watanabe M, Yagi K, Ohtahara S, Seino M. Clinical study of a new antiepileptic drug, clobazam, on efficacy and resistance in refractory epilepsies. J. Jpn. Epil. Soc. 20(1), 11-18 (2002). (Pubitemid 34288974)
59. Munn R, Camfield P, Camfield C, Dooley J. Clobazam for refractory childhood seizure disorders - A valuable supplementary drug. Can. J. Neurol. Sci. 15(4), 406-408 (1988). (Pubitemid 19002830)
60. Montenegro MA, Cendes F, Noronha AL et al. Efficacy of clobazam as add-on therapy in patients with refractory partial epilepsy. Epilepsia 42(4), 539-542 (2001). (Pubitemid 32322200)
61. Singh A, Guberman AH, Boisvert D. Clobazam in long-term epilepsy treatment: Sustained responders versus those developing tolerance. Epilepsia 36(8), 798-803 (1995).
62. Shorvon SD. The use of clobazam, midazolam, and nitrazepam in epilepsy. Epilepsia 39(Suppl. 1), S15-S23 (1998). (Pubitemid 28063387)
63. Wildin JD, Pleuvry BJ, Mawer GE, Onon T, Millington L. Respiratory and sedative effects of clobazam and clonazepam in volunteers. Br. J. Clin. Pharmacol. 29(2), 169-177 (1990). (Pubitemid 20131414)
64. Khosroshahi N, Faramarzi F, Salamati P, Haghighi SM, Kamrani K. Diazepam versus clobazam for intermittent prophylaxis of febrile seizures. Indian J. Pediatr. 78(1), 38-40 (2011).
65. McKernan RM, Rosahl TW, Reynolds DS et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype. Nat. Neurosci. 3(6), 587-592 (2000). (Pubitemid 30332078)
66. Mills JK, Lewis TG, Mughal K, Ali I, Ugur A, Whitehouse WP. Retention rate of clobazam, topiramate and lamotrigine in children with intractable epilepsies at 1 year. Seizure 20(5), 402-405 (2011).
67. Montenegro MA, Arif H, Nahm EA, Resor SR Jr, Hirsch LJ. Efficacy of clobazam as add-on therapy for refractory epilepsy: Experience at a US epilepsy center. Clin. Neuropharmacol. 31(6), 333-338 (2008).
68. Robertson MM. Current status of the 1,4- and 1,5- benzodiazepines in the treatment of epilepsy: The place of clobazam. Epilepsia 27(Suppl. 1), S27-S41 (1986). (Pubitemid 16027711)
69. Dalby MA. Clobazam in resistant epilepsy: A retrospective survey. In:Clobazam: Human Psychopharmacology and Clinical Applications . Hindmarch I, Stonier PD, Trimble MR (Eds). Royal Society of Medicine, London, UK, 189 (1985).
70. Watanabe M, Yagi K, Seino M. An open clinical trial of a newly developed antiepileptic drug, clobazam, on treatment-resistant epileptic seizures [In Japanese]. Saishin Igaku 34, 757-766 (1992).
71. Canadian Study Group for Childhood Epilepsy. Clobazam has equivalent efficacy to carbamazepine and phenytoin as monotherapy for childhood epilepsy. Epilepsia 39(9), 952-959 (1998).
72. Heller AJ, Ring HA, Reynolds EH. Factors relating to dramatic response to clobazam in refractory epilepsy. Epilepsy Res. 2(4), 276-280 (1988).
73. Haigh JR, Gent JP, Garratt JC et al. Disappointing results of increasing benzodiazepine dose after the development of anticonvulsant tolerance. J Neurol. Neurosurg. Psychiatry 51(7), 1008-1009 (1988).
74. Gastaut H, Tinuper P, Aguglia U, Lugaresi E. Treatment of certain forms of status epilepticus by means of single dose of clobazam [In French]. Rev. Electroencephalogr. Neurophysiol. 14(3), 203-206 (1984). (Pubitemid 15198627)
75. Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia 34(3), 453-468 (1993). (Pubitemid 23184580)
76. Markand ON. Lennox-Gastaut syndrome (childhood epileptic encephalopathy). J. Clin. Neurophysiol. 20(6), 426-441 (2003). (Pubitemid 38133970)
77. Beaumanoir A, Darvet C. The Lennox- Gastaut syndrome. In:Epileptic Syndromes in Infancy, Childhood and Adolescence (2nd Edition) . Roger J, Bureau M, Dravet CH, Dreifuss FE, Perret AWP (Eds). John Libbey Eurotext, London, UK, 115-132 (1992).
78. Crumrine PK. Lennox-Gastaut syndrome. J. Child Neurol. 17(Suppl. 1), S70-S75 (2002). (Pubitemid 34460814)
79. Wheless JW. Nonpharmacologic treatment of the catastrophic epilepsies of childhood. Epilepsia 45(Suppl. 5), 17-22 (2004). (Pubitemid 39060665)
80. Critchley EMR, Vakil SD, Hayward HW, Owen MV, Cocks A. Double-blind clinical study of clobazam in refractory epilepsy. In:Clobazam. Hindmarch I, Stonier PD (Eds). Royal Society of Medicine, London, UK, 159-163 (1981).
81. Feely M, Gibson J. Intermittent clobazam for catamenial epilepsy: Tolerance avoided. J. Neurol. Neurosurg. Psychiatry 47(12), 1279-1282 (1984). (Pubitemid 15178747)
82. Callaghan N, Goggin T. Clobazam as adjunctive treatment in drug resistant epilepsy - report on an open prospective study. Ir. Med. J. 77(8), 240-244 (1984). (Pubitemid 14000775)
83. Andrade R, García-Espinosa A, Machado- Rojas A, García-González ME, Trápaga- Quincoses O, Morales-Chacón LM. A prospective, open, controlled and randomised study of clobazam versus carbamazepine in patients with frequent episodes of Rolandic epilepsy [In Spanish]. Rev. Neurol. 49(11), 581-586 (2009).
84. Jan MM, Shaabat AO. Clobazam for the treatment of intractable childhood epilepsy. Saudi Med. J. 21(7), 622-624 (2000). (Pubitemid 30490668)
85. Silva RC, Montenegro MA, Guerreiro CA, Guerreiro MM. Clobazam as add-on therapy in children with epileptic encephalopathy. Can. J. Neurol. Sci. 33(2), 209-213 (2006). (Pubitemid 43845176)
86. Figueroa D, Adlerstein L, Manterola A. Clobazam in refractory epilepsies of children [In Spanish]. Rev. Chil. Pediatr. 55(6), 401-405 (1984).
87. Dávila-Gutiérrez G, Mondragón-Pineda A, Alcalá-Negrete H. Usefulness of clobazam in the treatment of refractory epilepsy in children [In Spanish]. Bol. Med. Hosp. Infant Mex. 47(10), 694-647 (1990).
88. Gastaut H. The effect of benzodiazepines on chronic epilepsy in man (with particular reference to clobazam). In:Clobazam. Hindmarch I, Stonier P (Eds). Royal Society of Medicine, London, UK, 141-150 (1981).
89. Bravaccio F, D'Ambrosio G, De Rosa A, Tata MR, Volpe E. The anti-epileptic properties of a diazepine drug (clobazam). Preliminary results. [In Italian]. Acta. Neurol. Quad. 39, 58-64 (1979).
90. Pechadre JC, Beudin P, Devoize JL, Gibert J. [Anti-epileptic effect of clobazam in Lennox-Gastaut syndrome]. Encephale 7(2), 181-190 (1981). (Pubitemid 11096092)
91. Franceschi M, Ferini-Strambi L, Mastrangelo M. Clobazam in drug-resistant and alcoholic withdrawal seizures. Clin. Study J. 20, 119-125 (1983). (Pubitemid 13094754)
92. Guberman A, Couture M, Blaschuk K, Sherwin A. Add-on trial of clobazam in intractable adult epilepsy with plasma level correlations. Can. J. Neurol. Sci. 17(3), 311-316 (1990). (Pubitemid 20254757)
93. Smith GC, Pell JP. Parachute use to prevent death and major trauma related to gravitational challenge: Systematic review of randomised controlled trials. BMJ 327(7429), 1459-1461 (2003). (Pubitemid 38045824)
94. Sachdeo RC, Glauser TA, Ritter F, Reife R, Lim P, Pledger G. A double-blind, randomized trial of topiramate in Lennox- Gastaut syndrome. Topiramate YL Study Group. Neurology 52(9), 1882-1887 (1999). (Pubitemid 29260904)
95. Felbamate Study Group in Lennox- Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome). N. Engl. J. Med. 328(1), 29-33 (1993).
96. Motte J, Trevathan E, Arvidsson JF, Barrera MN, Mullens EL, Manasco P. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Lamictal Lennox-Gastaut Study Group. N. Engl. J. Med. 337(25), 1807-1812 (1997). (Pubitemid 28006785)
97. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 70(21), 1950-1958 (2008).
98. Ng YT. A case of symptomatic, lesional epilepsy (hypothalamic hamartoma) masquerading as a generalized epilepsy with Lennox-Gastaut syndrome. Sem. Pediatr. Neurol. 17(1), 13-15 (2010).
99. Wyllie E, Lachhwani DK, Gupta A et al. Successful surgery for epilepsy due to early brain lesions despite generalized EEG findings. Neurology 69(4), 389-397 (2007). (Pubitemid 47205667)